The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | L | Antineoplastic and immunomodulating agents | |
| 2 | L02 | Endocrine therapy | |
| 3 | L02A | Hormones and related agents | |
| 4 | L02AA | Estrogens |
| Code | Title | |
|---|---|---|
| L02AA01 | Diethylstilbestrol | |
| L02AA02 | Polyestradiol phosphate | |
| L02AA03 | Ethinylestradiol | |
| L02AA04 | Fosfestrol |
| Active Ingredient | Description | |
|---|---|---|
| Diethylstilbestrol |
Diethylstilbestrol is a synthetic nonsteroidal estrogen, that was widely used to prevent potential miscarriages by stimulating the synthsis of estrogen and progesterone in the placenta. It was also used for the treatment of symptoms arising during menopause and following ovariectomy and for senile vaginitis and vulvar dystrophy. Diethylstilbestrol was used as a postcoital emergency contraceptive (morning-after pill). It has also been used for the prevention of postpartum breast engorgement, for dysfuctional menstrual cycles and for the treatment of female hypogonadism. Diethylstilbestrol is now rarely used to treat prostate cancer and occacionally in postmenopausal women with breast cancer because of its side-effects. |
|
| 17 alpha-Ethinylestradiol |
Ethinylestradiol is chemically and biologically identical to endogenous human oestradiol. It substitutes for the loss of estrogen production in menopausal women, and alleviates menopausal symptoms. Estrogens prevent bone loss following menopause or ovariectomy. |
|
| Fosfestrol |
|
